國立虎尾科技大學 |

Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches/ by Daniel Yuan Qiang Wong.
作者:	Wong, Daniel Yuan Qiang.
面頁冊數:	XXX, 147 p. 89 illus., 47 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Medicinal chemistry. -
電子資源:	https://doi.org/10.1007/978-981-10-8594-9
ISBN:	9789811085949

Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches
Wong, Daniel Yuan Qiang.

Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches[electronic resource] /by Daniel Yuan Qiang Wong. - 1st ed. 2018. - XXX, 147 p. 89 illus., 47 illus. in color.online resource. - Springer Theses, Recognizing Outstanding Ph.D. Research,2190-5053. - Springer Theses, Recognizing Outstanding Ph.D. Research,.

Introduction- Cisplatin- Now and Future -- Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum (IV) Prodrugs -- Probing the Platinum(IV) Prodrug Hypothesis - Are Platinum(IV) Complexes Really Prodrugs of Cisplatin? -- Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs -- Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents -- Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes -- Concluding Remarks.

This thesis describes the authors’ pioneering efforts in the conceptualization and implementation of combined platinum-based immuno-chemotherapeutics, which represent a significant paradigm shift from the conventional approach of directly targeting cancer. The work described has opened up a rich and largely unexplored area for platinum-based drug design, and ultimately paves the way for superior immuno-chemotherapeutics with better clinical outcome for patients. Historically, the contribution of the immune system to chemotherapy outcomes has been neglected, as anticancer drugs were believed to be immunosuppressive. However, this has been challenged by contemporary evidence suggesting that many chemotherapeutics, including platinum-based agents, stimulate the innate and/or adaptive immune system and that these “secret allies” contribute tangibly to clinical outcomes. A multi-pronged immuno-chemotherapeutic approach not only shrinks tumors, but more importantly, reactivate dormant immune responses to malignancies, eliminating residual cancer cells.

ISBN: 9789811085949

Standard No.: 10.1007/978-981-10-8594-9doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches
LDR:03096nam a22004095i 4500 001 994942
003 DE-He213
005 20200705093355.0
007 cr nn 008mamaa
008 201225s2018 si | s |||| 0|eng d
020 $a 9789811085949 $9 978-981-10-8594-9
024 7 $a 10.1007/978-981-10-8594-9 $2 doi
035 $a 978-981-10-8594-9
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
100 1 $a Wong, Daniel Yuan Qiang. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1205863
245 1 0 $a Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches $h [electronic resource] / $c by Daniel Yuan Qiang Wong.
250 $a 1st ed. 2018.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2018.
300 $a XXX, 147 p. 89 illus., 47 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Springer Theses, Recognizing Outstanding Ph.D. Research, $x 2190-5053
505 0 $a Introduction- Cisplatin- Now and Future -- Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum (IV) Prodrugs -- Probing the Platinum(IV) Prodrug Hypothesis - Are Platinum(IV) Complexes Really Prodrugs of Cisplatin? -- Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs -- Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents -- Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes -- Concluding Remarks.
520 $a This thesis describes the authors’ pioneering efforts in the conceptualization and implementation of combined platinum-based immuno-chemotherapeutics, which represent a significant paradigm shift from the conventional approach of directly targeting cancer. The work described has opened up a rich and largely unexplored area for platinum-based drug design, and ultimately paves the way for superior immuno-chemotherapeutics with better clinical outcome for patients. Historically, the contribution of the immune system to chemotherapy outcomes has been neglected, as anticancer drugs were believed to be immunosuppressive. However, this has been challenged by contemporary evidence suggesting that many chemotherapeutics, including platinum-based agents, stimulate the innate and/or adaptive immune system and that these “secret allies” contribute tangibly to clinical outcomes. A multi-pronged immuno-chemotherapeutic approach not only shrinks tumors, but more importantly, reactivate dormant immune responses to malignancies, eliminating residual cancer cells.
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Medical biochemistry. $3 1254555
650 0 $a Cancer research. $3 1253664
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Cancer Research. $3 668358
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811085932
776 0 8 $i Printed edition: $z 9789811085956
776 0 8 $i Printed edition: $z 9789811341946
830 0 $a Springer Theses, Recognizing Outstanding Ph.D. Research, $x 2190-5053 $3 1253569
856 4 0 $u https://doi.org/10.1007/978-981-10-8594-9
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)